Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | ACLY | P53396 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | CCR4 | P51679 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21513797 | 1.00 | ALDH1A1 (0.50) | ALDH1A1ACLYMEN1KMT2AMAPT | |
| SCHEMBL358926 | 0.83 | PIK3CG (0.63) | SLC40A1PIK3CGCCR4PIK3CAMTOR | |
| SCHEMBL29969873 | 0.83 | CCR4 (0.64) | MAPTSLC40A1PIK3CGCCR4 | |
| SCHEMBL21513796 | 0.83 | CCR4 (0.64) | MAPTSLC40A1PIK3CGCCR4 | |
| SCHEMBL789565 | 0.80 | PIK3CA (0.57) | SLC40A1PIK3CGPIK3CAMTOR | |
| SCHEMBL15648432 | 0.79 | PIK3CG (0.49) | PIK3CGCCR4PIK3CAMTOR | |
| SCHEMBL13975439 | 0.79 | ACLY (0.55) | ALDH1A1ACLYMEN1KMT2ASLC40A1 | |
| SCHEMBL13976112 | 0.79 | SLC40A1 (0.58) | ALDH1A1ACLYMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13975919 | 0.78 | ACLY (0.53) | ALDH1A1ACLYMEN1KMT2ASLC40A1 | |
| SCHEMBL789512 | 0.78 | KEAP1 (0.55) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | ALDH1A1 3354/4885ACLY 1245/4885MEN1 2696/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | ALDH1A1 3354/4885ACLY 1245/4885MEN1 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.